当前位置: X-MOL 学术Ann. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire
Annals of Oncology ( IF 50.5 ) Pub Date : 2017-05-30 , DOI: 10.1093/annonc/mdx274
A. Le Bourgeois , M. Labopin , D. Blaise , P. Ceballos , S. Vigouroux , R. Peffault de Latour , A. Marçais , C.E. Bulabois , J.O. Bay , S. Chantepie , E. Deconinck , E. Daguindau , N. Contentin , I. Yakoub-Agha , J. Cornillon , M. Mercier , P. Turlure , A. Charbonnier , P.S. Rorhlich , S. N’Guyen , N. Maillard , T. Marchand , M. Mohty , P. Chevallier

Fludarabine/busulfan-based conditioning regimens are widely used to perform allogeneic stem-cell transplantation (allo-SCT) in high-risk non-Hodgkin lymphoma (NHL) patients. The impact of the dose intensity of busulfan on outcomes has not been reported yet.

中文翻译:

同种异体移植非霍奇金淋巴瘤成年患者的基于强度降低和毒性降低的基于氟达拉滨/环丁砜的清髓性调理方案:代表法国社会发展银行的格雷弗·德·莫雷等人的回顾性研究

基于氟达拉滨/环丁砜的调理方案已广泛用于高危非霍奇金淋巴瘤(NHL)患者的异基因干细胞移植(allo-SCT)。尚无关于白消安剂量强度对预后的影响的报道。
更新日期:2017-09-18
down
wechat
bug